BRIEF-Oncolytics Biotech announces registration pathway and clinical development plan
April 12 Oncolytics Biotech Inc -
* Announces registration pathway and clinical development plan
* Announced initial registration pathway and clinical development plan for reolysin, proprietary immuno-oncology viral agent
* Trial will recruit approximately 44 patients across up to six myeloma UK clinical trial network centres in UK
* Oncolytics and Celgene UK & Ireland are providing respective products for muk eleven
* Oncolytics is providing Reolysin and Celgene UK & Ireland is providing imnovid and revlimid Source text for Eikon: Further company coverage: